Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?

Area of Science:

• Infectious Diseases
• Microbiology
• Public Health

Background:

• Leprosy remains endemic globally, posing a significant public health challenge.
• Mycobacterium leprae, the causative agent, targets the reticuloendothelial and peripheral nervous systems.
• Current multidrug therapy (MDT) faces challenges with sub-optimal completion rates and emerging drug resistance.

Purpose of the Study:

• To review the current status of leprosy worldwide.
• To provide information on infectious agents, clinical manifestations, and diagnosis.
• To discuss current treatment, future perspectives, and strategies for targeted delivery therapy.

Main Methods:

• Literature review of leprosy disease status, treatment, and future strategies.
• Analysis of infectious agents, clinical manifestations, and diagnostic approaches.
• Exploration of current multidrug therapy (clofazimine, dapsone, rifampicin) and its limitations.

Main Results:

• Leprosy affects multiple countries, with Mycobacterium leprae as the primary agent.
• Sub-optimal treatment completion and drug resistance are significant challenges in current leprosy programs.
• Future strategies focus on improving targeted delivery therapies.

Conclusions:

• Despite MDT, leprosy control remains suboptimal due to treatment completion issues and drug resistance.
• Further research into efficient targeted delivery therapies is crucial for future leprosy management.
• A comprehensive understanding of the disease is essential for developing effective global strategies.